MARKET

PRAX

PRAX

Praxis Precision Medicines, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

27.62
+1.29
+4.90%
Closed 16:00 05/06 EDT
OPEN
26.42
PREV CLOSE
26.33
HIGH
28.00
LOW
25.90
VOLUME
130.94K
TURNOVER
--
52 WEEK HIGH
60.95
52 WEEK LOW
23.90
MARKET CAP
1.02B
P/E (TTM)
-14.6122
1D
5D
1M
3M
1Y
5Y
64 Biggest Movers From Yesterday
Gainers
Benzinga · 2d ago
Brooklyn ImmunoTherapeutics, Motus GI leads healthcare gainers; Ardelyx, Pacific Biosciences of California among major losers
Gainers: Brooklyn ImmunoTherapeutics (BTX) +38%, Motus GI MOTS +32%, CryoLife (CRY) +16%, Mesoblast MESO +14%, Arcutis Biotherapeutics (ARQT) +10%.Losers: Ardelyx (ARDX) -13%, Pacific Biosciences of California (PACB) -13%, ALX Oncology (ALXO) -11%, Keros T...
Seekingalpha · 6d ago
Praxis' PRAX-562 wins Orphan Drug designation for rare encephalopathy
The FDA has granted Orphan Drug designation to Praxis Precision Medicines' (PRAX) PRAX-562 for the treatment of SCN2A development and epileptic encephalopathy (SCN2A-DEE).Earlier this month, PRAX-562 received the same designation
Seekingalpha · 6d ago
Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE
PRAX-562 Phase 2 clinical trial for treatment of DEEs expected to initiate in first half of 2022CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating gen...
GlobeNewswire · 6d ago
Praxis Precision Medicines Receives FDA Orphan Drug Designation for PRAX-562 to Treat Encephalopathy
MT Newswires · 04/30 09:48
Praxis Precision Medicines Adds Neurology Expertise to Board of Directors with Appointment of Merit Cudkowicz, M.D.
GlobeNewswire · 04/29 12:55
Why Praxis Precision Medicine's Stock is Up During Today's Session
Why Praxis Precision Medicine's Stock is Up During Today's Session The Price And Volume Action In Praxis Precision Medicine's Stock Today
Benzinga · 04/26 17:15
Benzinga's Top Ratings Upgrades, Downgrades For April 26, 2021
 
Benzinga · 04/26 14:06
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRAX. Analyze the recent business situations of Praxis Precision Medicines, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRAX stock price target is 66.00 with a high estimate of 70.00 and a low estimate of 63.00.
EPS
Institutional Holdings
Institutions: 69
Institutional Holdings: 36.20M
% Owned: 98.51%
Shares Outstanding: 36.75M
TypeInstitutionsShares
Increased
0
0
New
69
36.20M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.09%
Pharmaceuticals & Medical Research
-0.30%
Key Executives
President/Chief Executive Officer/Director/Primary Contact
Marcio Souza
Co-Founder/Chief Scientific Officer
Steven Petrou
Co-Founder
David Goldstein
Other
Bernard Ravina
Director
Jeffrey Chodakewitz
Independent Director
Merit Cudkowicz
No Data
  • All
  • Financials
  • Insiders
More
About PRAX
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance. Its development stage products include PRAX-114, PRAX-944 and PRAX-562. PRAX-114 is an extrasynaptic-preferring gamma-aminobutyric acid-A (GABAA) receptor positive allosteric modulator (PAM) for the treatment of patients suffering from major depressive disorder (MDD) and perimenopausal depression (PMD). PRAX-944 is a differentiated selective small molecule inhibitor of T-type calcium channel, for the treatment of essential tremor (ET). PRAX-562 is the selective, persistent sodium current blocker in development for the treatment of a range of CNS disorders.

Webull offers kinds of Praxis Precision Medicines Inc stock information, including NASDAQ:PRAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRAX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRAX stock methods without spending real money on the virtual paper trading platform.